X0508 4 2025-12-29 0001842295 Maze Therapeutics, Inc. MAZE 0002050167 Dandekar Atul C/O MAZE THERAPEUTICS, INC. 171 OYSTER POINT BOULEVARD, SUITE 300 SOUTH SAN FRANCISCO CA 94080 false true false false CSBO 1 Common Stock 2025-12-29 4 M 0 72400 10.42 A 82903 D Common Stock 2025-12-29 4 S 0 66365 40.5116 D 16538 D Common Stock 2025-12-29 4 S 0 6035 41.1286 D 10503 D Common Stock 2025-12-30 4 M 0 100 10.42 A 10603 D Common Stock 2025-12-30 4 S 0 100 40.3600 D 10503 D Stock Option (Right to Buy) 10.42 2025-12-29 4 M 0 72400 0 D 2031-04-11 Common Stock 72400 74243 D Stock Option (Right to Buy) 10.42 2025-12-30 4 M 0 100 0 D 2031-04-11 Common Stock 100 74143 D This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. The reported total includes 1,562 shares of the Issuer's Common Stock acquired by the reporting person in one or more transactions with the Issuer pursuant to its Employee Stock Purchase Plan, which transactions are exempt pursuant to Rules 16a3(f)(1)(i)(B) and 16b3(c). The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.99 to $40.985 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 4 of this Form 4. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.99 to $41.51 per share, inclusive. The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025. /s/ Courtney Phillips, as attorney-in-fact 2025-12-31